Molecular markers in prognosis of colorectal cancer and prediction of response to treatment

Boris Pasche*, Mary Mulcahy, Al B. Benson

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

28 Scopus citations


Colorectal cancer is the third most common human malignancy. Direct observation and biopsy sampling by colonoscopy have provided unique opportunities to study the natural history of the disease. As a consequence, advances in the understanding of colorectal cancer pathogenesis have evolved more rapidly than with most other solid tumours. Numerous molecular events arising during the development of colorectal cancer have been sorted out over the past two decades. Despite these advances, predicting outcome and response to therapy is still a major challenge in the management of patients with colorectal cancer. Molecular and biochemical markers of colorectal cancer are greatly needed for diagnosis and prognosis as well as for the selection and monitoring of treatments. The purpose of this chapter is to provide a critical assessment of the usefulness of markers in the prognosis and prediction of response to treatment in colorectal cancer.

Original languageEnglish (US)
Pages (from-to)331-345
Number of pages15
JournalBailliere's Best Practice and Research in Clinical Gastroenterology
Issue number2
StatePublished - Apr 2002


  • Biomarker
  • Colorectal cancerPrognosis
  • EGFR, p27, E-cadherin, bcl-2, CD44
  • Her-2/neu
  • Microsatellite instability
  • Myc
  • Ras
  • TGF-beta
  • Thymidylate synthase
  • p21
  • p53

ASJC Scopus subject areas

  • Gastroenterology


Dive into the research topics of 'Molecular markers in prognosis of colorectal cancer and prediction of response to treatment'. Together they form a unique fingerprint.

Cite this